CARDIAC SAFETY RESEARCH CONSORTIUM

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update Meeting

December 6th, 2016
Meeting Agenda

7:45am-8:00am Breakfast

8:00am- 8:05am Welcome and Introduction- Philip Sager, MD (Stanford University)

8:05am-9:50 Session I: Overview

- The need for a new approach to assessing the proarrhythmic potential of drugs and Overview of CiPA- **Philip Sager, MD** (Stanford University)(15min)
- Talk on TdP mechanisms and theoretical justification for CiPA- **Craig January, MD** (University of Wisconsin)(15min)
- The impact of CIPA on drug discovery and development, implications, timelines- **Norman Stockbridge, MD, PhD** (FDA)(15min)

Discussion (60min)

Panelist: ***Doug Throckmorton (FDA)***
Robert Temple, MD (FDA)
Peter Kowey, MD (Lankeneau)

9:50am-11:35am Session II: In Silico Modeling and Ion Channel Approaches

- Overview, scientific approach, planned outputs, and how data will be used (Talk to explain to clinicians why they should be comfortable relying on in silico data and reference precedent where in silico evaluation is used for risk assessment eg ICHS10 – GTI = Genotoxic Impurity) **Tom Colatsky, PhD** (15min)
- Overview of ion channel testing strategy (channel and protocol selection), and summary of HT studies **Bernard Fermini, PhD** (Pfizer)(15min)
- Summary of manual ion channel results and next steps- **Wendy Wu, PhD** (FDA)(15min)
- In silico strategy: development, validation, proarrhythmic metrics, modelling output, key issues, and next steps- **Zhihua Li, PhD** (FDA)(15min)

Discussion (45min)

Panelist: **Gary Mirams, PhD** (University of Oxford)
Blanca Rodriguez, PhD (University of Oxford)
David Strauss, MD, PhD (FDA)

11:35am-1:05pm Session III: Myocyte Efforts

- Myocyte overview, role in CiPA, and metrics- **Gary Gintant, PhD** (AbbVie)(15min)
- Myocyte approaches to VSD and MEA testing- research studies and preliminary results (including Phase 2 studies; address key issues
  - VSD talk- **Godfrey Smith, PhD** (University of Glasgow)(10min)
  - MEA talk- **Daniel Millard, PhD** (Axion Biosystems)(10min)
- Japanese Stem Cell Efforts- **Yuko Sekino, PhD** (JiCSA)(10min)

Discusssion (45min)

Lunch 1:05-1:35pm

1:35pm- 3:10pm Session IV: Phase 1 ECG assessment Under CiPA

- New ECG biomarkers and their role; validation and results of experimental data; new planned study- **Jose Vicente, PhD** (FDA)(15min)
- Interpretations based on Phase 1 ECG assessments **David Strauss, MD, PhD** (FDA)(15min)
- Practical implications, workflow, and open source code- **Robert Kleiman, MD** (ERT)(15min)

Discussion (60min)

3:10pm-4:30pm Session V: CIPA Regulatory Acceptance and Implementation

- CiPA Package and regulatory approaches **TDB**(15min)
- CiPA Implementation: Challenges, timing, and opportunities with CIPA implementation **TBD** (20min)
- What is the data package required for CIPA regulatory acceptance
  - **Colette Strnadova, PhD** (Health Canada)(5min)
  - **Kaori Shinagawa, MD** (PDMA)(5min)
  - **Krishna Prasad, MD** (MHRA)(5min)
  - **Hans Kemmler, PhD** (Swiss Medic)(5min)
  - **Dan Bloomfield,** Merck(5min)
  - **Derek Leishman, PhD** (Eli Lilly)(5min)

Discussion(45min)

4:30pm-4:45pm Summary & Next Steps